130 related articles for article (PubMed ID: 24327333)
1. Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
Leone JP; Leone J; Vallejo CT; Pérez JE; Romero AO; Machiavelli MR; Romero Acuña L; Domínguez ME; Langui M; Fasce HM; Leone BA; Ortiz E; Iturbe J; Zwenger AO
Breast Cancer Res Treat; 2014 Jan; 143(2):313-23. PubMed ID: 24327333
[TBL] [Abstract][Full Text] [Related]
2. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
Ludovini V; Antognelli C; Rulli A; Foglietta J; Pistola L; Eliana R; Floriani I; Nocentini G; Tofanetti FR; Piattoni S; Minenza E; Talesa VN; Sidoni A; Tonato M; Crinò L; Gori S
BMC Cancer; 2017 Jul; 17(1):502. PubMed ID: 28747156
[TBL] [Abstract][Full Text] [Related]
3. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Chintamani ; Singhal V; Singh JP; Lyall A; Saxena S; Bansal A
BMC Cancer; 2004 Aug; 4():48. PubMed ID: 15310398
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment of breast cancer: a pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha.
Tonini G; Nunziata C; Prete SP; Pepponi R; Turriziani M; Masci G; Graziani G; Bonmassar E; De Vecchis L
Cancer Immunol Immunother; 1998 Nov; 47(3):157-66. PubMed ID: 9829841
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer.
Gwak G; Park K; Shin E; Han S; Kim JY; Kim H; Kim YD; Kim HJ; Kim KW; Bae BN; Yang KH; Cho H; Park SJ
J Breast Cancer; 2011 Sep; 14(3):223-8. PubMed ID: 22031805
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of children exposed in utero to chemotherapy for breast cancer.
Murthy RK; Theriault RL; Barnett CM; Hodge S; Ramirez MM; Milbourne A; Rimes SA; Hortobagyi GN; Valero V; Litton JK
Breast Cancer Res; 2014 Dec; 16(6):500. PubMed ID: 25547133
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research.
Janelsins MC; Mustian KM; Palesh OG; Mohile SG; Peppone LJ; Sprod LK; Heckler CE; Roscoe JA; Katz AW; Williams JP; Morrow GR
Support Care Cancer; 2012 Apr; 20(4):831-9. PubMed ID: 21533812
[TBL] [Abstract][Full Text] [Related]
8. The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer.
Li R; Zhao X; Huang Y; Li C; Liu L; Wang M; Wang J; Song Z
Cancer Biother Radiopharm; 2024 Mar; ():. PubMed ID: 38512710
[No Abstract] [Full Text] [Related]
9. Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
Tecza K; Pamula-Pilat J; Lanuszewska J; Butkiewicz D; Grzybowska E
Oncotarget; 2018 Feb; 9(10):9114-9136. PubMed ID: 29507678
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.
Radford J
J Clin Oncol; 2024 Jun; 42(16):1868-1870. PubMed ID: 38478798
[No Abstract] [Full Text] [Related]
11. Efficacy of a telephone-delivered sexually transmitted infection/human immunodeficiency virus prevention maintenance intervention for adolescents: a randomized clinical trial.
DiClemente RJ; Wingood GM; Sales JM; Brown JL; Rose ES; Davis TL; Lang DL; Caliendo A; Hardin JW
JAMA Pediatr; 2014 Oct; 168(10):938-46. PubMed ID: 25155070
[TBL] [Abstract][Full Text] [Related]
12. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Janni W; Sarosiek T; Karaszewska B; Pikiel J; Staroslawska E; Potemski P; Salat C; Brain E; Caglevic C; Briggs K; Desilvio M; Marini L; Papadimitriou C
Breast Cancer Res Treat; 2014 Feb; 143(3):493-505. PubMed ID: 24402830
[TBL] [Abstract][Full Text] [Related]
13. Financial incentives for smoking cessation in pregnancy: randomised controlled trial.
Tappin D; Bauld L; Purves D; Boyd K; Sinclair L; MacAskill S; McKell J; Friel B; McConnachie A; de Caestecker L; Tannahill C; Radley A; Coleman T;
BMJ; 2015 Jan; 350():h134. PubMed ID: 25627664
[TBL] [Abstract][Full Text] [Related]
14. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Flaherty LE; Othus M; Atkins MB; Tuthill RJ; Thompson JA; Vetto JT; Haluska FG; Pappo AS; Sosman JA; Redman BG; Moon J; Ribas A; Kirkwood JM; Sondak VK
J Clin Oncol; 2014 Nov; 32(33):3771-8. PubMed ID: 25332243
[TBL] [Abstract][Full Text] [Related]
15. Length of hospital stay after hip fracture and short term risk of death after discharge: a total cohort study in Sweden.
Nordström P; Gustafson Y; Michaëlsson K; Nordström A
BMJ; 2015 Feb; 350():h696. PubMed ID: 25700551
[TBL] [Abstract][Full Text] [Related]
16. Differentiation between traumatic tap and aneurysmal subarachnoid hemorrhage: prospective cohort study.
Perry JJ; Alyahya B; Sivilotti ML; Bullard MJ; Émond M; Sutherland J; Worster A; Hohl C; Lee JS; Eisenhauer MA; Pauls M; Lesiuk H; Wells GA; Stiell IG
BMJ; 2015 Feb; 350():h568. PubMed ID: 25694274
[TBL] [Abstract][Full Text] [Related]
17. Mass treatment with single-dose azithromycin for yaws.
Mitjà O; Houinei W; Moses P; Kapa A; Paru R; Hays R; Lukehart S; Godornes C; Bieb SV; Grice T; Siba P; Mabey D; Sanz S; Alonso PL; Asiedu K; Bassat Q
N Engl J Med; 2015 Feb; 372(8):703-10. PubMed ID: 25693010
[TBL] [Abstract][Full Text] [Related]
18. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
Mistry PK; Lukina E; Ben Turkia H; Amato D; Baris H; Dasouki M; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Shankar S; Solano MH; Ross L; Angell J; Peterschmitt MJ
JAMA; 2015 Feb; 313(7):695-706. PubMed ID: 25688781
[TBL] [Abstract][Full Text] [Related]
19. Integrated primary care for patients with mental and physical multimorbidity: cluster randomised controlled trial of collaborative care for patients with depression comorbid with diabetes or cardiovascular disease.
Coventry P; Lovell K; Dickens C; Bower P; Chew-Graham C; McElvenny D; Hann M; Cherrington A; Garrett C; Gibbons CJ; Baguley C; Roughley K; Adeyemi I; Reeves D; Waheed W; Gask L
BMJ; 2015 Feb; 350():h638. PubMed ID: 25687344
[TBL] [Abstract][Full Text] [Related]
20. An occupational therapy intervention for residents with stroke related disabilities in UK care homes (OTCH): cluster randomised controlled trial.
Sackley CM; Walker MF; Burton CR; Watkins CL; Mant J; Roalfe AK; Wheatley K; Sheehan B; Sharp L; Stant KE; Fletcher-Smith J; Steel K; Wilde K; Irvine L; Peryer G;
BMJ; 2015 Feb; 350():h468. PubMed ID: 25657106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
